MedTrace Logo

Effect of Saccharomyces Cerevisiae on the Improvement of Gastro-intestinal Disorders Associated to IBS With C Phenotype

NCT03150212 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 456

Last updated 2019-05-21

No results posted yet for this study

Summary

The main objective is to assess the effect of an 8-week daily supplementation with IbSium® (probiotic yeast Saccharomyces cerevisiae CNCM I-3856) on the improvement gastro-intestinal disorders associated to the type C IBS (constipation predominant).

Conditions

  • Constipation-predominant Irritable Bowel Syndrome

Interventions

DIETARY_SUPPLEMENT

Saccharomyces cerevisiae CNCM I-3856

2 capsules daily, just before the breakfast with a glass of water, during 8 weeks.

DIETARY_SUPPLEMENT

Placebo

2 capsules daily, just before the breakfast with a glass of water, during 8 weeks.

Sponsors & Collaborators

  • Lesaffre International

    lead INDUSTRY

Principal Investigators

  • Isabelle METREAU, MD · Biofortis Mérieux NutriSciences

  • Arnaud BOURREILLE, Doctor · Service d'Hépatogastroentérologie - CHU Nantes

  • Pierre DESREUMAUX, Professor · Service de Gastroentérologie - Hôpital Huriez, CHU Lille

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-03-20
Primary Completion
2019-05-09
Completion
2019-05-09

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03150212 on ClinicalTrials.gov